## **Charity Number: 1180844 CHARITABLE INCORPORATED ORGANISATION (CIO)** ## **TISSUE VIABILITY SOCIETY (TVS) WORKING NAME: SOCIETY OF TISSUE VIABILITY** **TRUSTEES' REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2022** **NORTHOVER & CO ACCOUNTANTS LTD CHARTERED ACCOUNTANTS** **132A BOURNEMOUTH ROAD CHANDLERS FORD, HAMPSHIRE SO53 3AL** ## **TISSUE VIABILITY SOCIETY (TVS)** ## **TABLE OF CONTENTS** |**Page 1**|Legal & Administrative Information| |---|---| |**Page 2**|Independent Examiner's Report| |**Page 3**|Income and Expenditure Account| |**Page 4**|Comparative Income and Expenditure Account| |**Page 5**|Balance Sheet| |**Pages 6 to 12**|Notes to the Financial Statements| |**Appendix 1**|Report of the Trustees| **1.** ## **TISSUE VIABILITY SOCIETY (TVS)** ## **LEGAL AND ADMINISTRATIVE INFORMATION** Tissue Viability Society is an unincorporated entity and a registered charity governed by its memorandum and articles of association. The charity adopted a working name of Society of Tissue Viability, which was voted upon at the 2021 AGM and was formally adopted by the charity in February 2022. The legal name of the charity remains unchanged at this time. **CHARITY NUMBER 1180844 DATE OF REGISTRATION 26 November 2018** ## **TRUSTEES** |**TRUSTEES**||| |---|---|---| |**CHAIR**|**Jeannie Donnelly**|| |**VICE-CHAIR**|**Linda Primmer**|**Resigned July 2022**| ||**Sarah Gardner**|**_From July 2022_**| |**TREASURER**|**Fran Norman**|**_Until July 2022_**| ||**David Hibbitt**|**_From July 2022_**| |**DEUPTY TREASURER**|**Sarah Gardner**|**_Until July 2022_**| ||**Kate Williams**|**_From July 2022_**| |**OTHER TRUSTEES**|**Srinivasa Budithi**|**Appointed July 2022**| ||**Ina Farrelly**|| ||**Clare Greenwood**|| ||**Natasha Levy**|| ||**Liang Liu**|**Resigned July 2022**| ||**Victoria Murray**|| ||**Sharon Neill**|| ||**Jane Nixon**|**Resigned July 2022**| ||**Samantha Rooney**|**Appointed July 2022**| ||**Sharon Scattergood**|**Appointed July 2022**| ||**Joanna Swan**|| ||**Gill Sykes**|| ||**Connie Traynor**|| ||**Samantha Wharton**|| ||**Peter Worsley**|**Appointed July 2022**| |**PRINCIPAL ADDRESS**|**Clinical Trials Research Unit**|| ||**University of Leeds**|| ||**Leeds**|| ||**LS2 9JT**|| |**ACCOUNTANTS**|**Northover & Co. Accountants Ltd**|| ||**(Michael Northover TD FCA)**|| ||**132A Bournemouth Road,**|| ||**Chandlers Ford,**|| ||**Hampshire**|| ||**SO53 3AL**|| |**BANKERS**|**Lloyds Bank PLC**|| ||**120 Lewisham High Street**|| ||**London**|| ||**SE13 6JG**|| **TISSUE VIABILITY SOCIETY (TVS)** **2.** ## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF TISSUE VIABILITY SOCIETY** I report on the accounts of the company for the year ended 31st December 2022 which are set out on pages 3 to 12. ## **RESPECTIVE RESPONSIBILITIES OF THE TRUSTEES AND EXAMINER** The trustees are responsible for the preparation of the accounts and they consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is permissible. Having satisfied myself that the charity is not subject to an audit and is eligible for independent examination, it is my responsibility to: **examine the accounts under section 145 of the 2011 Act;** **follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and** **state whether particular matters have come to my attention.** ## **BASIS OF INDEPENDENT EXAMINER’S REPORT** My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below. ## **INDEPENDENT EXAMINER’S STATEMENT** In connection with my examination, no matter has come to my attention: - (1) which gives me reasonable cause to believe that, in any material respect, the requirements: to keep accounting records in accordance with section 386 of the Companies Act 2006; and to prepare accounts which agree with the accounting records and comply with the accounting requirements of section 396 of the Companies act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities have not been met; or - to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to - (2) be reached. ## Mike Northover ….................................................................................................... ## 07/09/23 Date…........................................................................................ ## **M A Northover TD FCA on behalf of** **NORTHOVER & CO ACCOUNTANTS LIMITED CHARTERED ACCOUNTANTS 132A BOURNEMOUTH ROAD CHANDLERS FORD, HAMPSHIRE** **SO53 3AL** **3.** ## **TISSUE VIABILITY SOCIETY (TVS) STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST DECEMBER 2022** ## **SUMMARY INCOME AND EXPENDITURE ACCOUNT** |**Notes**
**INCOMING RESOURCES**
Incoming resources from generated funds
Project income
( 4 )
Subscriptions
Donations and legacies
( 6 )
Investment income
( 7 )
Other income
**TOTAL INCOMING RESOURCES**
**RESOURCES EXPENDED**
Project expenditure
( 4 )
Strategy/mission expenditure
( 8 )
Charitable activities
( 9 )
**TOTAL EXPENDITURE**
**NET INCOMING RESOURCES**
**FOR THE YEAR BEFORE TRANSFERS**
Transfers between funds
**NET INCOME/(DEFICIT) FOR THE YEAR**
Total funds brought forward
**TOTAL FUNDS CARRIED FORWARD**|**Notes**||**Restricted**|**Unrestricted**
**Funds**
**2022**
_2021_
**95,822**
**415,103**
_307,377_
**20,316**
**20,316**
_16,125_
**301**
**301**
_930_
**22**
**22**
_4_
**-**
**-**
_-_
**116,461**
**435,742**
_324,436_
**81,734**
**295,705**
_217,847_
**7,749**
**7,749**
_710_
**61,547**
**61,547**
_52,839_
**151,030**
**365,001**
_271,396_
**(34,569)**
**70,741**
_53,040_
**57,725**
**-**
_-_
**23,156**
**70,741**
_53,040_
**157,028**
**276,239**
_223,199_
**180,184**
**346,980**
_276,239_
**TOTAL FUNDS**| |---|---|---|---|---| ||||**Funds**
**319,281**
**-**
**-**
**-**
**-**
**319,281**
**213,971**
**-**
**-**
**213,971**
**105,310**
**(57,725)**
**47,585**
**119,212**
**166,797**|| The Income and Expenditure Account includes all gains and losses recognised in the year. All income and expenditure derives from continuing activities. **4.** ## **TISSUE VIABILITY SOCIETY (TVS) STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST DECEMBER 2022** ## **COMPARATIVE SUMMARY INCOME AND EXPENDITURE ACCOUNT** |**Notes**
**INCOMING RESOURCES**
Incoming resources from generated funds
Project income
( 5 )
Subscriptions
Donations and legacies
( 6 )
Investment income
( 7 )
Other income
**TOTAL INCOMING RESOURCES**
**RESOURCES EXPENDED**
Project expenditure
( 5 )
Strategy/mission expenditure
( 8 )
Charitable activities
( 9 )
**TOTAL EXPENDITURE**
**NET INCOMING RESOURCES**
**FOR THE YEAR BEFORE TRANSFERS**
Transfers between funds
**NET INCOME/(DEFICIT) FOR THE YEAR**
Total funds brought forward
**TOTAL FUNDS CARRIED FORWARD**||Restricted
Funds
_202,545_
_-_
_-_
_-_
_-_
_202,545_
_161,366_
_-_
_-_
_161,366_
_41,179_
_4,000_
_45,179_
_74,033_
_119,212_|Unrestricted
Funds
_104,832_
_16,125_
_930_
_4_
_-_
_121,891_
_56,481_
_710_
_52,839_
_110,030_
_11,861_
_(4,000)_
_7,861_
_149,166_
_157,027_|TOTAL
FUNDS
_2021_
_307,377_
_16,125_
_930_
_4_
_-_
_324,436_
_217,847_
_710_
_52,839_
_271,396_
_53,040_
_-_
_53,040_
_223,199_
_276,239_| |---|---|---|---|---| **5.** ## **TISSUE VIABILITY SOCIETY (TVS) STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST DECEMBER 2022** |**CURRENT ASSETS**
Debtors
Cash at bank and in hand
**CREDITORS:**
Amounts falling due within one year
**NET CURRENT ASSETS**
**NET ASSETS**
**CAPITAL**
**Unrestricted funds**
General fund
**Restricted funds**|**Notes**

( 12 )
( 13 )
( 14 )
( 15 )|**2022**

**204,789**
**172,772**
**377,561**
**30,581**
**30,581**
**346,980**
**346,980**
**180,184**
**166,797**
**346,980**|_2021_
_133,942_
_167,912_
_301,854_
_25,615_
_25,615_
_276,239_
_276,239_
_157,028_
_119,212_
_276,239_| |---|---|---|---| The financial statements were approved by the board on……..................................... 19 September 2023 and signed on its behalf by: ………………………………………..................................... ## **Jeannie Donnelly** Chair **TISSUE VIABILITY SOCIETY (TVS) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2022** **6.** ## **1 ACCOUNTING POLICIES** ## **1.11 Basis of preparation of financial statements** The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011. Tissue Viability Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. ## **1.12 Fund accounting** General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes. Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund are set out in the notes to the financial statements. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. ## **1.13 Income** All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation. ## **1.14 Expenditure** Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements. Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. ## **1.15 Tangible fixed assets** The cost of tangible fixed assets, if any, is expended to the Income & Expenditure Account in the periods of acquisition. Website design costs, if any, are written off in the year they are incurred. ## **1.16 Debtors** Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. ## **1.17 Cash at bank and in hand** Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. ## **1.18 Creditors** Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due. **TISSUE VIABILITY SOCIETY (TVS) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2021** **7.** ## **1 ACCOUNTING POLICIES (cont.)** ## **1.19 Financial instruments** The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument. Basic financial assets, which include debtors and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised. Basic financial liabilities, including creditors, are initially recognised at transaction price and are subsequently carried at amortised cost using the effective interest method. Financial liabilities classified as payable within one year are not amortised. ## **1.20 Taxation** The charity is exempt from corporation tax on its charitable activities. ## **1.21 Going concern** At the time of approving the financial statements and after considering various possible levels of impact of Covid-19, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the holding trustees continue to adopt the going concern basis of accounting in preparing the financial statements. ## **2 TRUSTEES' RESPONSIBILITIES IN RESPECT OF THE FINANCIAL STATEMENTS** The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial period which give a true and fair view of the charity’s financial activities during the year and of its financial position at the end of the year. In preparing financial statements giving a true and fair view, the trustees should follow best practice and: •select suitable accounting policies and then apply them consistently; •make judgements and estimates that are reasonable and prudent; •state whether applicable accounting standards and statements of recommended practice have been followed, subject to any departures disclosed and explained in the financial statements; •prepare the financial statements on the going concern basis unless it is inappropriate to presume that the society will continue in operation. The trustees are responsible for keeping accounting records which disclose with reasonable accuracy the financial position of the society and which enable them to ascertain the financial position of the society and which enable them to ensure that the financial statements comply with applicable law. They are also responsible for safeguarding the assets of the society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. ## **3 RESERVES POLICY** The charity regulations require the society to define its policy in respect of reserves. The trustees consider that as it no longer has full time employees with a permanent base, that it hold sufficient reserves to insure that it can continue its activities satisfactorily for a period of least 12 months even if its income was significantly reduced. However the Trustees do consider the Charity’s ongoing viability on an annual basis. Any funds and ongoing income not required for immediate needs is put on deposit to maximise interest and drawn upon as required. **TISSUE VIABILITY SOCIETY (TVS) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2022** **8.** ## **4 TOTAL PROJECT INCOME & EXPENDITURE** ## **PROJECT INCOME & EXPENDITURE - UNRESTRICTED** |**2022**
**Income**
**Expenditure**
**Surplus/**
**(Deficit)**
Journals
**31,632**
**23,352**
**8,280**
Education Programme Facilitator
**-**
**9,904**
**(9,904)**
Corporate Sponsors - 40% donation element
**40,880**
**-**
**40,880**
Educational Endorsements
**10,500**
**6,500**
**4,000**
Study Days
**12,810**
**21,945**
**(9,135)**
Webinars
**-**
**700**
**(700)**
WReN
**-**
**19,333**
**(19,333)**
**95,822**
**81,734**
**14,088**
**PROJECT INCOME & EXPENDITURE - RESTRICTED**|_2021_
_Surplus/_
_(Deficit)_
_5,656_
_(1,383)_
_43,600_
_7,408_
_(2,382)_
_150_
_(4,698)_
_48,351_| |---|---| ||Educational Grants
TVS Conference
Legs Matter Project
Skin Care Champions
Stop the Pressure| |---|---| |**TOTAL PROJECT INCOME & EXPENDITURE**
**Income**
**Expenditure**
**Surplus/**
**(Deficit)**
**415,103**
**295,705**
**119,398**
**5 TOTAL PROJECT INCOME & EXPENDITURE (COMPARATIVE)**
**PROJECT INCOME & EXPENDITURE - UNRESTRICTED (COMPARATIVE)**|**TOTAL PROJECT INCOME & EXPENDITURE**
**Income**
**Expenditure**
**Surplus/**
**(Deficit)**
**415,103**
**295,705**
**119,398**| ||**TOTAL PROJECT INCOME & EXPENDITURE**
**Income**
**Expenditure**
**Surplus/**
**(Deficit)**| |---|---| ||**415,103**
**295,705**
**119,398**| |**5 **|**TOTAL PROJECT INCOME & EXPENDITURE (COMPARATIVE)**
**PROJECT INCOME & EXPENDITURE - UNRESTRICTED (COMPARATIVE)**| |Journals
Education Programme Facilitator
Corporate Sponsors - 40% donation element
Educational Endorsements
Study Days
Webinars
WReN|_Income_
_Expenditure_
_24,988_
_19,332_
_-_
_1,383_
_44,800_
_1,200_
_14,200_
_6,792_
_13,344_
_15,726_
_7,000_
_6,850_
_500_
_5,198_
_104,832_
_56,481_|_2021_
_Surplus/_
_(Deficit)_
_5,656_
_(1,383)_
_43,600_
_7,408_
_(2,382)_
_150_
_(4,698)_
_48,351_| |---|---|---| **TISSUE VIABILITY SOCIETY (TVS) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2022** **9.** ## **5 TOTAL PROJECT INCOME & EXPENDITURE (COMPARATIVE) (CONT.)** ## **PROJECT INCOME & EXPENDITURE - RESTRICTED (COMPARATIVE)** |Educational Grants
TVS Conference
Legs Matter Project
Skin Care Champions
Stop the Pressure|_Income_
_Expenditure_
_59,100_
_-_
_45,226_
_73,116_
_71,289_
_66,733_
_21,680_
_12,585_
_5,250_
_8,932_
_202,545_
_161,366_|_Surplus/_
_(Deficit)_
_59,100_
_(27,890)_
_4,556_
_9,095_
_(3,682)_
_41,179_| |---|---|---| |**TOTAL PROJECT INCOME & EXPENDITURE (COMPARATIVE)**
_Income_
_Expenditure_
_307,377_
_217,847_
**6 DONATIONS AND LEGACIES**
**2022**
Donations
**301**
**7 INVESTMENT INCOME**
**2022**
Interest receivable
**22**
**8 STRATEGY/MISSION EXPENSES**
**2022**
EPUAP
**1,280**
EWMA
**1,794**
Scholarships
**4,467**
Other conferences
**208**
**7,749**
**9 CHARITABLE EXPENDITURE - UNRESTRICTED**
**2022**
**SUPPORT COSTS**
Marketing, website and rebranding costs
**38,220**
Administration assistant
**17,223**
Council expenses - trustees fees
**-**
Printing, postage and stationery
**28**
Paypal charges
**173**
Bank charges
**114**
Just Giving charges
**7**
Insurance
**1,270**
Subscriptions
**451**
Training
**-**
Meeting expenses
**632**
Sundry expenses
**229**
**58,347**|_Surplus/_
_(Deficit)_
_89,530_
_2021_
_930_
_2021_
_4_
_2021_
_-_
_-_
_-_
_710_
_710_
_2021_
_28,908_
_17,124_
_-_
_53_
_150_
_86_
_22_
_1,163_
_346_
_-_
_266_
_427_
_48,545_| |---|---| **TISSUE VIABILITY SOCIETY (TVS) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2022** **10.** |**9 CHARITABLE EXPENDITURE - UNRESTRICTED (CONT.)**
**GOVERNANCE COSTS**
Independent examination
Council expenses
**TOTAL CHARITABLE EXPENDITURE**|**2022**
**3,200**
**-**
**3,200**
**61,547**|_2021_
_4,294_
_-_
_4,294_
_52,839_| |---|---|---| ## **10 STAFF COSTS** The average number of staff employed during the year was 0 (2021: 0). There were no employees whose annual remuneration was £60,000 or more. ## **11 TRUSTEES REMUNERATION AND EXPENSES** During the year, amounts were paid/reimbursed to the trustees of the charity as follows: |Speaker fees
Educational endorsement fees
Educational Programme Facilitator
Consultant fees
Travel expenses|**2022**
**2,040**
**-**
**8,464**
**1,794**
**2,781**
**15,079**|_2021_
_950_
_908_
_-_
_-_
_366_
_2,224_| |---|---|---| Speaker fees were paid to 3 Trustees (2021: 1) for preparation and speaking at society Study Days. Education endorsement fees were paid to 0 Trustees (2021: 2) for review work undertaken on educational materials as part of the Educational Endorsement offering. Education Programme Facilitator fees were paid to 1 Trustee for consultancy work on the organisation of study days and other organisational work regarding the annual conferences and other charity services. No remuneration was paid to any Trustees during the year. ## **12 DEBTORS** |Trade debtors
Amounts due from Pink@Pink TVS Ltd
Prepayments and accrued income
**13 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade creditors
Accruals and deferred income|**2022**
**31,632**
**172,022**
**1,135**
**204,789**
**2022**
**2,979**
**27,602**
**30,581**|_2021_
_24,988_
_107,965_
_989_
_133,942_
_2021_
_1,441_
_24,174_
_25,615_| |---|---|---| **11.** ## **TISSUE VIABILITY SOCIETY (TVS) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2022** |**14 UNRESTRICTED FUNDS**
General funds
**15 RESTRICTED FUNDS**
Educational Grants
TVS Conference
Legs Matter
Skin Care Champions
STOP the Pressure|**Funds**
**Funds**
**B/Fwd**
**Income**
**Expenditure**
**Transfers**
**C/Fwd**
_157,028_
**116,461**
**(151,030)**
**57,725**
**180,184**
_157,028_
**116,461**
**(151,030)**
**57,725**
**180,184**
**Funds**
**Funds**
**B/Fwd**
**Income**
**Expenditure**
**Transfers**
**C/Fwd**
_58,180_
**61,800**
**-**
**(119,980)**
**-**
_31,456_
**200,674**
**(171,517)**
**54,930**
**115,543**
_22,623_
**49,737**
**(20,681)**
**-**
**51,679**
_10,635_
**2,070**
**(14,773)**
**-**
**(2,068)**
_(3,682)_
**5,000**
**(7,000)**
**7,325**
**1,643**
_119,212_
**319,281**
**(213,971)**
**(57,725)**
**166,797**| |---|---| ## **Educational Grants** The charity receives sponsorship through direct sponsorship or through our tiered corporate membership system to provide grants to healthcare professionals to enable them to attend the TVS conferences and exhibitions. The healthcare professionals will receive a grant to cover travel and accommodation costs for the event, as well as covering the cost of attending the events. ## **TVS Conference** The charity holds an annual conference covering a wide range of topics within the remit of the charity to enhance the knowledge and awareness of these topics for healthcare professionals across the country. The charity receives sponsorship and grants to enable this conference to be held. ## **Legs Matter** Legs Matter is a coalition of organisations working together to increase awareness, understanding and action on lower leg and foot conditions among the public and healthcare professionals through year-round activities and communications. ## **Skin Care Champions** Skin Care Champions provides people working in care homes and home care agencies a trusted programme of cost-effective and easily accessible education and support skin health and wound healing. ## **STOP the Pressure** Stop The Pressure aims to create a significant culture shift and eliminate avoidable pressure ulcers in acute, community and mental health provider settings through a variety of activities to support healthcare professional, including hosting free webinars with expert speakers leading informative sessions, putting together training sessions for organisations and developing graphics and posters which can be adapted locally. ## **16 ANALYSIS OF NET ASSETS BETWEEN FUNDS** |_As at 31 December 2022_
Debtors
Bank and Cash
Creditors
_As at 31 December 2021_
Debtors
Bank and Cash
Creditors|**Unrestricted**
**Restricted**
**2022**
**42,967**
**161,822**
**204,789**
**167,797**
**4,975**
**172,772**
**(30,271)**
**(310)**
**(30,581)**
**180,493**
**166,487**
**346,980**
**Unrestricted**
**Restricted**
**2021**
_25,977_
_107,965_
_133,942_
_156,665_
_11,247_
_167,912_
_(25,615)_
_-_
_(25,615)_
_157,027_
_119,212_
_276,239_| |---|---| **12.** ## **TISSUE VIABILITY SOCIETY (TVS) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2022** ## **17 RELATED PARTIES** Pink@Pink TVS Ltd is a company registered in England and Wales (Company Number: 08199801) which acts on behalf on Tissue Viability Society in the organisation and management of several of the charity's funds and events. The company is currently owned and managed by individuals whom are not trustees of the charity. The charity maintains oversight of the financial dealings of the company through regular management reporting by the company to the charity. Listed below is an overall summary of the transactions which have been undertaken on behalf of the charity. ||**2022**|_2021_| |---|---|---| |Income|**383,058**|_266,392_| |Expenditure|**319,001**|_246,361_| |Amounts due from Pink@Pink TVS Ltd - Disclosed within Debtors|**172,022**|_107,965_| |||**Trustees' Annual Report for theperiod**|**Trustees' Annual Report for theperiod**|**Trustees' Annual Report for theperiod**|**Trustees' Annual Report for theperiod**|**Trustees' Annual Report for theperiod**|**Trustees' Annual Report for theperiod**|**Trustees' Annual Report for theperiod**|**Trustees' Annual Report for theperiod**| |---|---|---|---|---|---|---|---|---|---| ||**From **|Period start date||||**To**|Period end date||| ||||||||||| |||1st||January|2022||31st|December|2022| ||||||||||| |Section A||Reference and administration details|||||||| |**Charity name**
**Registered charity number**
**Charity's principal address**|||||||||| ||||Tissue Viability Society (TVS)
known as Society of Tissue Viability||||||| ||||||||||| ||||1180844||||||| ||||||||||| ||||c/o The Clinical Trials Research Unit, University of Leeds,
Leeds LS2 9JT||||||| ## **Names of the charity trustees who manage the charity. Trustees are elected by the council or members.** ||**Trustee name**|**Office (if any)**|**Dates acted if not for whole year**| |---|---|---|---| |1.|Jeannie Donnelly|Chair|Since 2020, Chair since July2021| |2.|Sarah Gardner|Vice Chair, Legs Matter
lead|Since 2018, Vice Chair since July 2022| |3.|David Hibbitt|Treasurer
Industryrepresentative|Since 2018, Treasurer since July 2022| |4.|Kate Williams|Vice Treasurer|Since 2018, Vice Treasurer since July2022| |5.|Srinivasa Budithi||Since 2022| |6.|Ina Farrelly||Since 2019| |7.|Clare Greenwood||Since 2021| |8.|Natasha Levy||Since 2020| |9.|LiangLiu||Since 2019, resigned July2022| |10.|Victoria Murray|Industryrepresentative|Since 2021| |11.|Sharon Neill||Since 2020| |12.|Jane Nixon||Since October 2020, resigned July2022| |13.|Frances Norman
(was Spratt)||Since 2018| |14.|Linda Primmer||Since 2018, resigned July2022| |15.|Samantha Rooney||Since 2022| |16.|Sharon Scattergood||Since 2022| |17.|Joanna Swan||Since 2018| |18.|Gill Sykes||Since 2018| |19.|Connie Traynor||Since 2018| |20.|Samantha Wharton||Since 2021| |21.|Peter Worsley||Since 2022| Society of Tissue Viability Annual Report 1 July 2023 ## **Section B Structure, governance and management** ## **Description of the charity’s trusts** Type of governing Constitution document How the charity is A Council of Trustees constituted Trustee selection methods Appointed by Council or elected by membership depending upon number of available places and number of applicants. ## **Section C Objectives and activities** The objectives for which the Society is established are to promote learning and advance public education in the study of tissue viability and **Summary of the objects of** do all such things as may be conducive to improve standards in tissue **the charity set out in its** viability as a multi-professional activity. **governing document** _All Trustees are aware of the public benefit guidance issued by the Charity Commission and have had regard to this when making decisions to undertake activities._ The start of 2022 once again saw the Pandemic as a continuing threat to the Society’s plans, with the Board of Trustees assessing whether to postpone the Society’s annual conference in Glasgow, 18–19 May. A risk assessment considered factors such as strong enthusiasm for the conference, high educational grant applications, committed exhibitors and companies keen for a face to face conference to happen, versus the possibility of moving the conference to later in the year when pressure on the NHS might have eased, and assessing the financial risk if lock down was again reimposed, especially in respect of the different rules that **Summary of the main activities undertaken for** applied in Scotland. With everything taken into consideration, it was decided to move forward at risk with a face-to-face conference and this, **the public benefit in** as it turned out, proved to be the right decision. Our 2022 conference at **relation to these objects** Hampden Park, Glasgow was a resounding success and once again the highlight of the Society’s year. The conference was also an opportunity to showcase our new brand and ethos. Since 2020 Trustees had been working on a revised strategy and this work presented an opportunity to review the Tissue Viability Society’s (TVS) brand and website to make sure they were working as hard as they could to support the strategic ambitions of the Society. The world and tissue viability have changed since the inception of the TVS in 1980 and the Pandemic accelerated that change. The rebrand was an opportunity to take stock and reassess the role and relevance of the TVS and how it could be reflected in a new brand. Society of Tissue Viability Annual Report 2 July 2023 Key findings from stakeholder interviews and a survey showed that the TVS had some great strengths – integrity, credibility, trust but there was lack of clarity about the mission and role of the Society; there was no strong sense of the value of membership or who it was for and there was a need to be more inter-disciplinary, not just a society for TVNs. Our working name was changed to the Society of Tissue Viability (a subtle yet powerful change) and our brand purpose was relaunched – ‘We use the power of collaborative thinking and action to solve skin and wound challenges’. We created a new visual identify with a new logo, a refreshed colour pallet, a range of illustrations to allow us to build recognition in a more unique way than using photography alone and, of course, a new website with enhanced functionality. The impact of the new brand has been considerable across all areas of Society business. Our social media channels have shown significant engagement and growth and the increase in website page views has been remarkable. Prior to the website re-launch, we typically had 200 to 500 page views per day. This has now increased to an impressive 500 to 1,000+ page views per day and so demonstrating the undoubted success of the rebranding project. Coinciding with our change of name and new brand, our highly regarded journal, the _Journal of Tissue_ Viability (JTV), also experienced a change in leadership and structure. In April 2022, Professor Dan Bader (now deceased) handed over the role of Editor in Chief to Professor Declan Patton of the School of Nursing and Midwifery, Royal College of Surgeons Ireland. Professor Bader remained on the editorial team as Emeritus Editor to assist in the handover and support the new editor. In addition, the Society’s links with the journal were strengthened with the inclusion of Trustees Clare Greenwood and Natasha Levy on the editorial board, and the appointment of existing board member Peter Worsley as a Trustee of the Society. Dan Bader was very proud to hand over the journal in such good shape, with the JTV securing its highest ever Impact Factor of 3.374 in 2022. Very sadly, in November 2022 Dan Bader unexpectedly died; this was not only a huge shock and loss to his family, but also to the Society and he is very much missed by all who knew him. Below is a short summary providing further detail of the main activities the Society has undertaken in 2022 in support of its strategic objectives. **1. Membership** Being a member of the Society of Tissue Viability means joining a community of some of the world’s best clinical experts and helping to shape and contribute to the science and research of skin health and wound healing. The Society was set up for all those who are passionate about solving skin and wound challenges and we welcome anyone who is interested in skin health and wound healing – whether professionally or personally. Over the course of 2022 our membership has grown strongly and by the close of the year stood at over 700 members. Many members are nurses, but our community also includes doctors, pharmacists, bioengineers, podiatrists, other allied health professionals, academics, researchers, clinical scientists and healthcare industry professionals and it is this diversity in our community that is one of our main strengths. In 2022 we launched a new initiative for members, called the Active Associate, which is an opportunity for members to become more involved in the work of the Society. This new intitiavie followed on from our setting up in 2021 the Alumni group of former Trustees in order to retain their Society of Tissue Viability Annual Report 3 July 2023 wealth of knowledge and organisational memory. The two groups were brought together under the banner of the Associate Forum and we officially launched this initiative at our conference in Glasgow. The Associate Forum had its first meeting in June 2022 and now has 26 Active Associate members. We hope that in time Active Associates will become embedded in the work streams of the Society and that the Forum may prove a stepping stone for members to ultimately take up the role of Trustee. We hope that the Forum will generate its own initiatives based on its members’ interests and areas of expertise which will go on to feed into our educational programmes and conference. **2. Conference** It was a welcome return to a face-to-face meeting for our 2022 conference held at Hampden Park, Glasgow on 18–19 May. The conference was run in collaboration with the National Association of Tissue Viability Nurses Scotland (NATVNS) and we introduced industry sponsored breakfast symposia which were a great success. The packed two-day programme included lectures, discussion forums and workshops plus the Wounds Research Network’s 7th Scientific Meeting and a full day ‘Fundamentals in Skin Health and Wound Healing’ event. Attending conferences is one of the very best ways to access the latest knowledge and build invaluable professional connections, but we know the cost for individuals can be prohibitive. That is why the Society created educational grants, a simple, transparent and cost-effective way for us, with the support of our industry partners, to fund healthcare professionals to attend our annual conference, as well as other conferences. 419 Clinical delegates registered over the two days of the Glasgow conference, with 67 speakers, 47 exhibiting companies and 135 industry personnel registered. Coming out of the Pandemic, the event was a great success and gave us a platform to build on for the 2023 annual conference in Peterborough. A major focus of the 2022 conference was to continue with our commitment to a greener way of working – the programme booklet was very much reduced with all information accessed through our website, and any new conference materials were commissioned with a view to their reuse. Finally, by filming many sessions we are building up a valuable library of on-demand assets for our members’ future use which we believe will be invaluable to them. Unfortunately, due to the uncertainty of Pandemic early in the year, Trustees took the tough decision not to attend EWMA 22 Paris as a Society. Later in the year, however, Trustees did attend EPUAP 22 in Prague and educational grants provided by the Society also supported two members to attend EPUAP. **3. Study sessions** The Society offers regular, virtual education sessions for all, whether someone is just embarking on their career or has many years’ experience. These educational sessions are an invaluable way of increasing knowledge, and all sessions are free for delegates to attend. In 2022 we changed the format of our Foundation study days. Previously these study days combined both pressure ulcers and wound care in one session and, while they proved extremely successful, in 2022 we moved to a programme that offered three Fundamental half-day sessions on: Society of Tissue Viability Annual Report July 2023 4 - Pressure ulcer prevention and management - Wound assessment and management - • Lower limb care By revising the format, the Society was able to offer new and more indepth information to delegates. As part of this new format, in July 2022 we held a Fundamental study session on lower limb care specifically for our industry partners. The study session was designed to enhance their knowledge in order to support our members’ practice. For all our study sessions, we continued to use the breakout room functionality in Zoom so our industry partners can showcase their products and services in a virtual exhibition environment. We consistently receive excellent feedback from both delegates and industry representatives for our Fundamental sessions. Our Advanced study sessions, designed for those who are confident in wound assessment and dressing selection, included full-day events on: - Prevention and management of pressure ulcers in patients with complex physical and mental health needs, - Advances in lower limb and foot care - Advances in surgical wound management and reducing surgical site infection. Service specific study session topics included - Wound care for children - Skin health and wound healing in mental health settings - • Optimising skin health and wound healing in palliative care settings During 2022 we educated a total of 1,369 healthcare professionals, and from January to June 2023 we have so far educated a total of 930. For the second half of 2023, we are making some changes to our study sessions in order to enhance the experience, both for attendees and our industry supporters. In future we will be using Zoom Webinar and utilising the breakout room facility, offering industry time within the programme to take over the ‘main stage’ in order that they can present to the whole audience about their products and services. **Webinars** The Society continues to run webinars both independently and in partnership with commercial organisations. Both options have resulted in extremely lively sessions with a valuable learning experience for all delegates and lots of questions. Webinars held over 2022 and to date in 2023 include: - Atypical causes of leg ulceration, a live webinar with Sweta Rai, Consultant Dermatologist and Dermatologic Surgeon - PURPOSE T Risk Assessment, part of 2022’s Stop the Pressure week - Sponsored by Accel-Heal, Wound pain: can we do better? Transforming our patient’s quality of life, using nonpharmacological approaches in wound pain management - • Sponsored by Healthy.io, Unlocking the potential of wound care: Strategies for successful digital transformation projects All webinars were viewable live on Zoom and streamed to the Facebook Live platform. Following the event, they were made available to watch ondemand on the Society’s website and YouTube channel. Over 2,000 people viewed these events on the various channels, and they are continuing to get views. Society of Tissue Viability Annual Report July 2023 5 ## **Skin Care Champions** The Society created the Skin Care Champions programme to provide people working in care homes and home care agencies with trusted, cost-effective and easily accessible education that supports skin health and wound healing. Our ambition is to create and empower a Skin Care Champion for every care home or agency that joins the programme – someone who can help to make sure that excellent care is provided to their clients and residents and be seen a source of information and knowledge for their peers. Following the launch of our Skin Care Champion programme in 2021, we ran a second cohort in 2022 with 34 champions enrolled. While the monthly meetings achieved relatively low attendance figures, our website’s statistics clearly showed that the meeting recordings and module information were being viewed and downloaded regularly. The programme was once again very well evaluated with participants particularly appreciating the supportive community of like-minded people and the opportunity to share experiences with the network. Our Skin Care Champions programme is delivered by Heidi Sandoz, a highly respected leading educator in wound care. Under Heidi’s guidance the Skin Care Champions programme has continued to gain momentum by word of mouth and through social channels. This, combined with a noticeable increase in engagement shown by our second cohort, convinced Trustees to support a third cohort of champions. In addition, the financial model for the programme was rethought and included applying to 3M for a grant, which we were awarded in April 2023. A third cohort of Skin Care Champions started in May 2023 and it really feels like the Society’s vision to ‘ignite the potential for great skin care in the social care sector’ is starting to come together as the 2023 programme has 81 champions registered. ## **Education Endorsement** A core part of the Society’s mission is to make sure that the best new thinking and practice in skin health and wound healing reaches the people it needs to. Our offering of Education Endorsement is a part of fulfilling this. We are proud to work with our industry partners and other not-for-profit organisations to help bring more high-quality, independent education to people with an interest in skin health and wound healing. During 2022 we endorsed 7 educational modules, for 2 organisations and so far during 2023, have endorsed 3 modules for 1 organisation, with many renewals and new materials to be endorsed in the pipeline for the second half of 2023. ## **4. Project work / consultations** The Society is regularly approached by external organisations nationally to offer opinion or consultation on work they may be doing. Largely this kind of work is undertaken without consulting the membership, but we are always mindful that we represent our membership when we respond. Project work and consultations this year have included: ## v _Legs Matter Campaign:_ Legs Matter continues to actively raise awareness of lower limb and foot health, gaining interest from both patients and the public as well as healthcare professionals. v The campaign is run by a coalition of like-minded organisations under the governance of the Society. In 2022 the coalition Society of Tissue Viability Annual Report 6 July 2023 - decided not to hold its annual awareness week, but instead to embark on a period of reflection and analysis, enabling the group to consider whether the campaign was delivering the right tools to the right people. - v The Legs Matter website (legsmatter.org) is the campaign’s major tool, and in 2022 the coalition concentrated on improving the website and making it more accessible to a wider range of people. A Search Engine Optimisation (SEO) analysis was carried out, which identified specific sections of the website that required improvement if search engines (and therefore people) are to find the information they are searching for. Following the analysis, the coalition members began the process of updating these pages, a huge task which continues to be a work in progress. - v Also in 2022 an extensive stakeholder feedback exercise was conducted to evaluate the success of the campaign so far and look at resetting the campaign’s strategy for the future. Overall, those who provided feedback valued the campaign for raising awareness of leg and foot problems and for providing high quality, evidence-based information for patients and healthcare professionals. However, the coalition concluded that there were still hard to reach clinicians (such as GPs) and that raising our profile on various platforms such as social media would help the campaign filter through to these groups. - v The coalition also decided that a new campaign focus was required and agreed on switching the focus towards the ‘harm that results from sub-optimal leg and foot care’. This new focus follows on well from the campaign’s consensus document ‘Let’s Make Legs Matter: A case for change’ which was produced by the coalition and published at the end of 2021. This hard-hitting document challenged providers and commissioners of lower limb services and raised the need for an all-system approach to change if improvements for patients were to be made and harm avoided. The campaign continues to promote the document through various communication channels and educational events that the coalition has been involved in over the past year. - v In partnership with PINK Marketing, a campaign strategy for the new focus was developed and revised campaign objectives set. This led into informing the range of activities for the campaign’s 2023 awareness week, which took place on 12–16 June 2023 to raise the alarm on the hidden harm crisis in the treatment of leg and foot conditions. - v The website’s central importance to the Legs Matter campaign is revealed by its website statistics, with half a million page views over the past 12 months and an average time spent on the page of nearly three minutes, suggesting a high level of engagement. - v Social media continues to play an important role in communicating the key messages of the campaign with an increase in followers across all key platforms; Legs Matter’s Twitter page now has 6,108 followers, Facebook 4,270, LinkedIn 845 and Instagram 610. - v The campaign continues to receive excellent support from Industry through corporate sponsorship and their contribution to the campaign’s strategy. Legs Matter is fortunate to have this financial support, since without it the campaign would not be able to continue. At the time of writing this report, the Legs Matter campaign is in a positive financial position. Society of Tissue Viability Annual Report July 2023 7 - v _STOP the Pressure:_ In 2022 our first 4 nations #STOPTHEPRESSURE campaign was - launched. A joint initiative with representation from all 4 nations of the UK, it was run in collaboration with the National Wound Care Strategy Programme and was supported by our media partners Mark Allen Group and Wounds UK. - v The focus for the campaign was Risk Assessment and the PURPOSE T tool (everything was also made relevant for those using other risk assessment tools) and the aim was ‘to create a significant culture shift and eliminate avoidable pressure ulcers in all health and care settings’. - v The key elements of the 2022 campaign were: - A month-long social media campaign with a full ‘social media pack’ of downloadable assets and ideas to enable everyone to join in - A series of short films ranging from messages from the Chief Nurse Officers of all 4 nations as well as patient stories and risk assessment advice - Virtual events including a full day of advanced pressure ulcer management training, a pressure ulcer fundamentals session and PURPOSE T webinar - A range of activities and competitions including a #STOPTHEPRESSURE quiz and word search - • A range of downloadable assets including posters, banner stands and PowerPoint presentations - v The videos and some of the assets were uploaded to the Resource section of the Society’s website and are available on an ongoing basis. Work has already commenced on the 2023 campaign, which again will be a #4Nation collaboration, and we have also reached out to our industry partners and gained the support of 12 commercial organisations. - v _Wounds Research Network (WReN):_ The 7[th] annual Scientific Meeting of the Wounds Research Network (WReN) was held as part of our 2022 Conference in Glasgow. The theme of the meeting was around implementation, showcasing how research funded by National Institute for Health and Care Research (NIHR) is changing practice. - v WReN’s Scientific Committee continued to grow the NIHR portfolio on its dedicated website (woundsrn.org), highlighting NIHR programmes that are set up, actively recruiting or are completed. - v Following feedback from the 2022 Scientific Meeting, the format of WReN’s annual meeting was changed in 2023, whereby the focus on a research stream was run concurrently within the overall Society programme. It was felt that this approach made research more accessible to delegates and numbers on the day were encouraging, with around 60–80 delegates attending. ## v _NHS England:_ The Society continues to work with NHS England Improvement to lead a programme of change for the wound care population of England. - v In 2022 the National Wound Care Strategy Programme (NWCSP) approached the Society to investigate developing a piece of work seeking to explore students’ experience of wound care. Students are the future of wound care and, at the moment, their undergraduate experience seems to be hit or miss, particularly in Society of Tissue Viability Annual Report 8 July 2023 clinical practice. Following the NWCSP’s approach, the Society developed a survey for newly qualified healthcare professionals in order to understand how the level of education students receive correlates with their level of preparedness and confidence at the start of their practice as newly qualified healthcare professionals. v Also during 2022, the Society continued to engage with NHS Supply Chain, using the proper channels to raise clinicians concerns around sourcing specialist products. Keen to ensure that the views of our members and other healthcare professionals were represented in a clear and unbiased way, we developed a survey around the procurement of wound care products and therapies and the evidence for their use. v Both surveys were launched in November 2022 and continue to be open for submissions at the time of writing. v _Nurses Specialized in Wound, Ostomy and Continence Canada (NSWOCC)_ : In 2022 the Society continued collaborative working with NSWOCC around producing a joint consensus document on best practice in relation to sharp debridement. This collaborative document is due for publication in 2023. v _International Skin Tear Advisory Panel (ISTAP):_ In 2021 the Society signed a memorandum of understanding with the International Skin Tear Advisory Panel to form a partnership to raise awareness about the prevention and management of skin tears and skin breakdown. On 28 April 2022 the Society supported ISTAP’s inaugural global ‘A World Without Skin Tears’ Day via our social media channels and website. **5. Journal of Tissue Viability** The Society’s journal, the _Journal of Tissue Viability_ (JTV), is a high quality, peer reviewed journal that has an international readership. It is free to members and available to purchase on subscription by nonmembers. The JTV has seen a healthy increase in submissions over the past 4 years, with 293 articles submitted to the journal in 2022, showing an increase of 18% compared to 2021. Looking at 2023 year to date, the journal has seen a significant increase of 36% in submissions compared to January–June 2022. In terms of geographical performance, as has been the trend since 2019, submissions from Asia dominate and the gap between Asia and Europe widens year by year. As a journal of interest to readers worldwide, the JTV’s Science Direct portal broke the barrier of 200,000 users in 2022, with 45% of users originating in the United States. In addition, the usage figures in Clinical Key increased by 30% in 2022, peaking at 11,896. The journal was given an Impact Factor (IF) for 2021 (reported in 2022) of 3.374 (2020 IF 2.932) due to a huge 41% increase in citations to the JTV. The JTV went up significantly in ranking within the Nursing category – ranked 13 (first quartile); Dermatology category rank 24 (second quartile). For 2022 (reported in 2023) the journal has been given an IF of 2.5, ranking it as 34/123 (second quartile) in Nursing category and 33/70 (second quartile) in Dermatology category. An increase was also seen in CiteScore from 3.1 (2021) to 3.5 (2022), with the journal ranking as 43/133 in Dermatology category and as 76/193 in Pathology and Forensic Medicine category. Society of Tissue Viability Annual Report 9 July 2023 ## **7. Wider public engagement and public benefit** The Society contracts PINK Marketing to support its wider administrative needs, including conference organisation, involvement in strategy and projects, and managing our digital presence. In the 2022–2023 sponsorship year (1 June 2022–31 May 2023), PINK Marketing secured support from 18 industry sponsors to provide financial support as corporate partners for the Society. PINK manage the Society’s social media accounts. By year end, followers of the Society’s Twitter account had increased to 6,832 (up by 14.1%), Facebook to 5,4341 followers (up by 13.9%), LinkedIn to 1,955 (up by 25.9%), and Instagram increased to 295 followers (up by 57.8%). In addition, at the end of 2022 there were 5,087 people subscribed to receive the Society’s informative e-newsletter. Society of Tissue Viability Annual Report 10 July 2023 ## Section D Achievements and performance ## **Summary of the main achievements of the charity during the year** **Highlights of the Society’s achievements in 2022:** - **2022 conference:** quickly taking the decision to proceed with a face-to-face conference, our annual conference is Glasgow was a resounding success attracting over 400 delegates. - • **New identity:** In early 2022 the Society adopted its new working name of Society of Tissue Viability, launching a new logo, brand and website with increased functionality. The enormous amount of work involved behind this was rewarded with a substantial increase in membership and traffic to our website. - **Associate Forum:** to help members get actively involved with the Society’s work we created the role of Active Associate. Combined with our Alumni group we set up the Associate Forum for these two groups to share their knowledge, experience and interests to feed back into the Society’s work streams. - **Study sessions** : we revised the format of our Foundation study days, now called Fundamentals, and split these into three distinct areas, which enabled the Society to offer new and more in-depth information to attendees. Advanced study sessions were held on topics such as the lower limb and surgical site infection, and we introduced Service Specific sessions on topics such as wound care for children, and for mental health and palliative settings. - • **Webinars** : a programme of webinars was put together by the Education Group on topics such as atypical leg ulceration and PURPOSE T risk assessment. - • **Skin Care Champions** : to support and provide first rate tissue viability education to carers in domiciliary and care home settings a second cohort of our Skin Care Champions was launched with 34 champions successfully completing the programme. - **Education Endorsement** : in 2022 our Education Endorsement service, which aims to review generic educational materials provided by our industry partners to ensure quality for users across the UK, endorsed modules from 2 organisations. - • **Legs Matter** : a year of strategic reflection and reassessment based on extensive stakeholder feedback led to a new campaign focus on the hidden harm that results from sub-optimal leg and foot care. This was supported by detailed background work on the campaign’s website to increase its accessibility to a wider range of users. - **STOP the Pressure** : for 2022 we launched a joint initiative with a campaign that had representation from all 4 nations of the UK, and which was run in collaboration with the National Wound Care Strategy Programme and supported by media partners Mark Allen Group and Wounds UK. The focus for the campaign was Risk Assessment and using the PURPOSE T tool. - • **Wounds Research Network (WReN):** held its 7[th] Scientific Meeting alongside the Society’s annual conference in Glasgow. With a theme around implementation, it showcased how research funded by the National Institute for Health and Care Research (NIHR) is changing practice. - • **Membership surveys:** in 2022 we launched two surveys; one to assess the level of wound care education and confidence in newly Society of Tissue Viability Annual Report 11 July 2023 Section D Achievements and performance qualified healthcare professionals; and a second around the procurement of wound care products and therapies and the evidence for their use. Both these surveys were confined to NHS England practitioners. • **Journal of Tissue Viability** : The JTV also saw a big rise in its Impact Factor to 3.374 and its Science Direct portal broke the barrier of 200,000 users. In 2022 Professor Declan Patton was appointed the new Editor in Chief. Credit and thanks must go to the Society’s dedicated Trustees and all those associated with our Council including PINK Marketing (Sue Simmonds, Kerry Wiles and Dawn Rush) and administrator Charlotte Hurdman, all of whom work consistently hard and passionately for the charity. Not forgetting our enthusiastic members, partners in industry and _Journal of Tissue Viability_ without whom the Society would not be what it is today. The Council of Trustees and Society of Tissue Viability is comprised of people united in their passion for wound care and skin health and their drive to help solve the challenges of wound care as part of a much wider collaborative approach. ## **Section E Financial review** The Trustees are committed to maintaining financial reserves equivalent **Brief statement of the** to one year’s running costs. **charity’s policy on reserves Details of any funds** The Society is not currently in deficit **materially in deficit** ## **Section F Other optional information** ## **Section G Declaration** **The trustees declare that they have approved the trustees’ report above.** **Signed on behalf of the charity’s trustees** |**Section G Declaration**|**Section G Declaration**|**Section G Declaration**| |---|---|---| |**The trustees declare that they have approved the trustees’ report above.**
**Signed** **on behalf of the charity’s trustees**||| |**Signature(s)**||| |**Full name(s)**|Elizabeth Jean Donnelly|| |**Position (e.g. Secretary,**
**Chair, etc.)**|Chair of the Council of Trustees|| |**Date**|06/09/2023|| Society of Tissue Viability Annual Report 12 July 2023